An integrated approach for inference and mechanistic modeling for advancing drug development

FEBS Letters

Volumn 579, Issue 8, 2005, Pages 1878-1883

  Aksenov, Sergej V ^a   Church, Bruce ^a   Dhiman, Anjali ^a   Georgieva, Anna ^b   Sarangapani, Ramesh ^b   Helmlinger, Gabriel ^c   Khalil, Iya G ^a  

^a Gene Network Sciences Inc   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

Biomarker; Computational biology; Drug development; Efficacy; Omic; Systems biology; Toxicity

Indexed keywords

1 [[6 (3 METHOXYESTRA 1,3,5(10) TRIEN 17BETA YL)AMINO]HEXYL] 1H PYRROLE 2,5 DIONE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BORTEZOMIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LEUKOTRIENE RECEPTOR BLOCKING AGENT;

BAYES THEOREM; COMPUTER SIMULATION; DRUG SYNTHESIS; GENE EXPRESSION PROFILING; GENE FUNCTION; HUMAN; MATHEMATICAL MODEL; MOLECULAR DYNAMICS; MOLECULAR MODEL; NONHUMAN; PRIORITY JOURNAL; PROBABILITY; SHORT SURVEY;

EID: 14844300115     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2005.02.012     Document Type: Short Survey

References (42)

1. J. Becker Signal transduction inhibitors - a work in progress Nat. Biotech. 22 2004 15 18
2. J. Dancey, and E.A. Sausville Issues and progress with protein kinase inhibitors for cancer treatment Nat. Rev. Drug Discov. 2 2003 296 313
3. R. Frank, and R. Hargreaves Clinical biomarkers in drug discovery and development Nat. Rev. Drug Discov. 2 2003 566 580
4. Stoughton, R.B., Friend, S.H. (2005). How molecular profiling could revolutionize drug discovery. Nat Rev Drug Discov. in press
5. N.C. Dracopoli Pharmacogenomic applications in clinical drug development Cancer Chemother. Pharmacol. 52 Suppl. 1 2003 S57 S60
6. J. Quackenbush Computational analysis of microarray data Nat. Rev. Genet. 2 2001 418 427
7. P. Shannon Cytoscape: a software environment for integrated models of biomolecular interaction networks Genome Res. 13 2003 2498 2504
8. L. Bonetta Bioinformatics - from genes to pathways Nat. Meth. 1 2004 169 176
9. T.S. Gardner, D. di Bernardo, D. Lorenz, and J.J. Collins Inferring genetic networks and identifying compound mode of action via expression profiling Science 301 2003 102 105
10. T. Akutsu, S. Miyano, and S. Kuhara Inferring qualitative relations in genetic networks and metabolic pathways Bioinformatics 16 2000 727 734
11. A. Arkin, P. Shen, and J. Ross A test case of correlation metric construction of a reaction pathway from measurements Science 277 1997 1275 1279
12. P. D'Haeseleer, S. Liang, and R. Somogyi Genetic network inference: from coexpression clustering to reverse engineering Bioinformatics 16 2000 707 726
13. N. Friedman, M. Linial, I. Nachman, and D. Pe'er Using Bayesian networks to analyze expression data J. Comput. Biol. 7 2000 601 620
14. A.J. Hartemink, D.K. Gifford, T.S. Jaakkola, and R.A. Young Combining location and expression data for principled discovery of genetic regulatory network models Pac. Symp. Biocomput. 2002 437 449
15. S. Liang, S. Fuhrman, and R. Somogyi Reveal, a general reverse engineering algorithm for inference of genetic network architectures Pac. Symp. Biocomput. 1998 18 29
16. D.C. Weaver, C.T. Workman, and G.D. Stormo Modeling regulatory networks with weight matrices Pac. Symp. Biocomput. 1999 112 123
17. H. Xu, P. Wu, C.F. Wu, C. Tidwell, and Y. Wang A smooth response surface algorithm for constructing a gene regulatory network Physiol. Genom. 11 2002 11 20
18. D. Husmeier Reverse engineering of genetic networks with Bayesian networks Biochem. Soc. Trans. 31 2003 1516 1518
19. V.A. Smith, E.D. Jarvis, and A.J. Hartemink Evaluating functional network inference using simulations of complex biological systems Bioinformatics 18 Suppl. 1 2002 S216 S224
20. V.A. Smith, E.D. Jarvis, and A.J. Hartemink Influence of network topology and data collection on network inference Pac. Symp. Biocomput. 2003 164 175
21. J. Yu, V.A. Smith, P.P. Wang, A.J. Hartemink, and E.D. Jarvis Advances to Bayesian network inference for generating causal networks from observational biological data Bioinformatics 20 2004 3594 3603
22. N. Friedman Inferring cellular networks using probabilistic graphical models Science 303 2004 799 805
23. A.H. Tong A combined experimental and computational strategy to define protein interaction networks for peptide recognition modules Science 295 2002 321 324
24. E. Yeger-Lotem, S. Sattath, N. Kashtan, S. Itzkovitz, R. Milo, R.Y. Pinter, U. Alon, and H. Margalit Network motifs in integrated cellular networks of transcription-regulation and protein-protein interaction Proc. Natl. Acad. Sci. USA 101 2004 5934 5939
25. P.M. Bowers, S.J. Cokus, D. Eisenberg, and T.O. Yeates Use of logic relationships to decipher protein network organization Science 306 2004 2246 2249
26. H. Resat, J.A. Ewald, D.A. Dixon, and H.S. Wiley An integrated model of epidermal growth factor receptor trafficking and signal transduction Biophys. J. 85 2003 730 743
27. Z. Qu, J.N. Weiss, and W.R. MacLellan Regulation of the mammalian cell cycle: a model of the G1-to-S transition Am. J. Physiol. Cell Physiol. 284 2003 C349 C364
28. B. Novak, and J.J. Tyson A model for restriction point control of the mammalian cell cycle J. Theor. Biol. 230 2004 563 579
29. M. Maeda, S. Lu, G. Shaulsky, Y. Miyazaki, H. Kuwayama, Y. Tanaka, A. Kuspa, and W.F. Loomis Periodic signaling controlled by an oscillatory circuit that includes protein kinases ERK2 and PKA Science 304 2004 875 878
30. B.S. Hendriks, L.K. Opresko, H.S. Wiley, and D. Lauffenburger Quantitative analysis of HER2-mediated effects on HER2 and epidermal growth factor receptor endocytosis: distribution of homo- and heterodimers depends on relative HER2 levels J. Biol. Chem. 278 2003 23343 23351
31. J.M. Haugh, A. Wells, and D.A. Lauffenburger Mathematical modeling of epidermal growth factor receptor signaling through the phospholipase C pathway: mechanistic insights and predictions for molecular interventions Biotechnol. Bioeng. 70 2000 225 238
32. B. Goldstein, J.R. Faeder, W.S. Hlavacek, M.L. Blinov, A. Redondo, and C. Wofsy Modeling the early signaling events mediated by FcepsilonRI Mol. Immunol. 38 2002 1213 1219
33. A. Hoffmann, A. Levchenko, M.L. Scott, and D. Baltimore The IkappaB-NFkappaB signaling module: temporal control and selective gene activation Science 298 2002 1241 1245
34. M.H. Sung, and R. Simon in silico simulation of inhibitor drug effects on nuclear factor-kappaB pathway dynamics Mol. Pharmacol. 66 2004 70 75
35. R. Christopher Data-driven computer simulation of human cancer cell Ann. N. Y. Acad. Sci. 1020 2004 132 153
36. C.J. Musante, A.K. Lewis, and K. Hall Small- and large-scale biosimulation applied to drug discovery and development Drug Discov. Today 7 2002 S192 S196
37. C.G. Moles, P. Mendes, and J.R. Banga Parameter estimation in biochemical pathways: a comparison of global optimization methods Genome Res. 13 2003 2467 2474
38. K.S. Brown, and J.P. Sethna Statistical mechanical approaches to models with many poorly known parameters Phys. Rev. E 68 2003 021904
39. S. Nishizuka Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays Proc. Natl. Acad. Sci. USA 100 2003 14229 14234
40. S.D. Patterson, and R.H. Aebersold Proteomics: the first decade and beyond Nat. Genet. 33 Suppl. 2003 311 323
41. Blagoev, B., Ong, S.-E., Kratchmarova, I. and Mann, M. (2004) Temporal analysis of phosphotyrosine-dependent signaling networks by quantitative proteomics. 22, 1139-1145
42. Maimon, R. and Browning, S. (2001) In: 2nd International Conference on Systems Biology